Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Waypoint Bio raises $20M in Series A funding to run three CAR-T trials in China.
PRIVATEMay 27, 2026•2 months ago
Amount Raised
$20 Million
Round Type
Series A
New YorkBiotechnologyHealth CareTherapeutics
Description
New York City-based startup Waypoint Bio has raised $20 million in Series A financing. The funding will be used to test multiple cell therapies in China. This round is aimed at advancing the company's clinical trials.
Company Information
Company
Waypoint Bio
Location
New York, New York, United States
About
Waypoint Bio is a biotechnology company pioneering novel cell therapies for solid tumors using in vivo spatial pooled screening technology. The company's platform uniquely combines spatial biology with pooled screening for the purpose of drug discovery, enabling the simultaneous measurement of cell therapy candidates' navigation in the solid tumor microenvironment. Waypoint will use its seed financing toward designing CAR T-cell therapies with superior efficacy against the tumor microenvironment, and later, Treg therapies for autoimmune diseases.
Related People
Suggested for you
1 contact
Verified contactsDavid P., Co-founder and CSO hidden
Predictive Intelligence
Strategic
ML-powered predictions for Waypoint Bio's next move
New YorkBiotechnologyHealth CareTherapeutics